INTENSITY THERAPEUTICS ($INTS) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.96 per share, beating estimates of -$1.11 by $0.15. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $INTS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INTENSITY THERAPEUTICS Hedge Fund Activity
We have seen 15 institutional investors add shares of INTENSITY THERAPEUTICS stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SAPIENT CAPITAL LLC removed 624,145 shares (-96.0%) from their portfolio in Q1 2026, for an estimated $3,669,972
- ROTHSCHILD WEALTH LLC removed 472,616 shares (-95.3%) from their portfolio in Q1 2026, for an estimated $2,778,982
- VANGUARD GROUP INC added 393,151 shares (+153.6%) to their portfolio in Q4 2025, for an estimated $161,270
- MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. removed 236,882 shares (-94.4%) from their portfolio in Q1 2026, for an estimated $1,392,866
- GEODE CAPITAL MANAGEMENT, LLC added 201,357 shares (+77.8%) to their portfolio in Q4 2025, for an estimated $82,596
- LEGACY ADVISORS, LLC removed 153,447 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $902,268
- CREATIVE PLANNING added 143,136 shares (+inf%) to their portfolio in Q4 2025, for an estimated $58,714
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
